{"prompt": "['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 17 of 61', 'Medtronic', '4. Introduction', '4.1. Background', 'One of the most common patient complaints about sacral neuromodulation (SNM) for overactive', 'bladder (OAB) is unwanted or uncomfortable stimulation. 1,2 It is often assumed that higher amplitude', 'stimulation will provide better efficacy, but there is a lack of clinical evidence regarding amplitude', 'effects of SNM for OAB. However, there is some evidence that SNM for fecal incontinence is effective at', 'sub-sensory threshold/amplitude.\u00b3 This study will explore whether lower amplitude stimulation can', 'provide improved symptom control when compared to baseline. Potential effects of lower amplitude', 'may include changes in or sustained efficacy, or reduced patient complaints due to uncomfortable', 'stimulation. This feasibility study will provide an initial understanding of various amplitude stimulation', 'settings and the impact on symptoms.', 'The effect of amplitude on SNM therapy efficacy is not well characterized clinically for either OAB4 or', 'fecal incontinence5 However, preclinical data suggest the effect of SNM is amplitude-dependent. Using', 'the rodent model of rhythmic bladder contractions (RBC), Su et al (2012) showed that increasing', 'amplitude of spinal nerve stimulation from motor threshold amplitude to 3x motor threshold resulted in', 'inhibition of bladder contractions by 20 to 90%, respectively.6 Similarly, using the RBC model in cats,', 'Snellings and Grill (2012) showed that stimulation of the of the pudendal nerves inhibited the frequency', 'of contractions and increased bladder capacity at 0.8, 1, and 2 times motor threshold in an intensity-', 'dependent manner.7 Finally, stimulation of tibial nerve and dorsal nerve of the penis produced an', 'amplitude-dependent inhibition of bladder contractions in the rodent. 8 The sum of these studies', 'suggest that the effect of neuromodulation on bladder function is amplitude-dependent.', 'Duelund-Jakobsen et al (2013) demonstrated that there was no significant difference in reduction of', 'fecal incontinent episodes when subjects were programmed to 50%, 75%, and 100% of sensory', 'threshold (n=19).3 In a recent clinical study using fMRI, Gill et al demonstrated a stimulation amplitude-', 'dependent response in brain activity in 6 patients receiving sub-sensory, sensory, and supra-sensory', 'SNM.6 These studies suggest SNM efficacy at sub-sensory amplitudes.', 'Given the preclinical data showing an amplitude-dependent effect of neuromodulation on bladder', 'function and the clinical data demonstrating a therapeutic effect of sub-sensory amplitude, it is', 'important to understand the efficacy of SNM at different subsensory and sensory threshold amplitudes.', '4.2. Purpose', 'The purpose of this prospective, multicenter, randomized, single-blind feasibility study is to explore the', 'efficacy and quality of life under 3 different amplitude settings (sub-sensory amplitudes of 50% and 80%', 'of sensory threshold and sensory threshold). Efficacy will be characterized with change from baseline', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 18 of 61', 'Medtronic', 'through 12 weeks in UUI episodes and patient reported outcomes. Quality of life will be characterized', 'with the ICIQ-OABqol Questionnaire at baseline and 12 weeks. Subject participation will last', 'approximately 16 weeks following the enrollment visit. Subjects are exited from the study after the 12-', 'week follow-up visit is completed.', '5. Objectives and Enppoints', '5.1. Objectives', '5.1.1.', 'Primary Objective', 'The primary objective in the study is to explore the effect of three different amplitude settings (50% of', 'sensory threshold, 80% of sensory threshold and sensory threshold) on number of UUI episodes per day', '5.1.2.', 'Secondary Objective', 'Secondary objective of this study is quality of life (ICIQ-OABqol) for the three different amplitude', 'settings.', '5.1.3.', 'Additional Measures', 'Additional measures include:', 'Safety', '6. Study Design', 'This is a prospective, multicenter, randomized, single-blind, feasibility study to explore the efficacy and', 'quality of life of 3 different amplitude settings in patients with UUI. Subjects will remain blinded to their', 'assigned randomization for the duration of the study.', 'Eligible subjects will sign a study-specific informed consent form (ICF). Following verification of eligibility', 'criteria, subjects will go through therapy evaluation with the InterStim II System. After qualifying for the', 'device implant, the subject will proceed with a neurostimulator device implant and randomization', 'procedures. Subjects will be randomized to one of the three amplitude settings: 50% of sensory', 'threshold, 80% of sensory threshold and sensory threshold.', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']\n\n###\n\n", "completion": "END"}